Expect ongoing selling pressure as the company likely draws on the ATM to fund operating losses. Monitor daily volume and market impact of ATM sales. Key catalyst: phase 1 data for JADE101 expected at ERA Congress, but dilution risk may cap upside.
Price Chart
Executive Summary
Jade Biosciences filed a $600M universal shelf registration statement, including a $200M at-the-market (ATM) equity offering via Jefferies, concurrent with a Q1 2026 earnings miss (EPS -$0.57 vs -$0.52 consensus) and widened net loss. The ATM could dilute existing shareholders by up to ~16% at current prices, reinforcing a bearish outlook as the company burns cash with no near-term revenue prospects.
Key Financial Metrics
Key Facts
- Filed S-3 shelf for up to $600M in securities, with $200M ATM component via Jefferies.
- Q1 2026 EPS -$0.57 vs consensus -$0.52; net loss widened to $40.4M from $38.2M YoY.
- Cash and investments declined to $311M from $336M as of Dec 2025.
- Proceeds from ATM to be used for working capital and general corporate purposes.
- At assumed price of $25.26/share, full $200M ATM would add ~7.9M shares, diluting existing holders by ~16%.
Financial Impact
Up to $200M in potential equity issuance, representing ~16% dilution at current market cap of $1.2B.
Risk Factors
- Significant dilution from potential ATM issuance.
- No approved products; pipeline setback could accelerate cash burn.
- Q1 earnings miss and widening losses increase urgency of capital raise.
- Market may perceive offering as a sign of financial weakness.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-212422 |
| Document: d132368dex45.htm | 0001193125-26-212422 |
| Document: d132368dex12.htm | 0001193125-26-212422 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $14.05 $13.77 | ▼ −1.99% | ▼ −3.91% | $14.50 (+3.20%) |
Aug 10, 2026 11w ago | 8-K | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Aug 10, 2026 11w ago | Press Release | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Jun 5, 2026 20w ago | Press Release | $14.98 $16.10 | ▼ −7.48% | ▼ −5.37% | $14.50 (+3.20%) |
Jun 4, 2026 20w ago | 8-K | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 4, 2026 20w ago | 424B5 | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | 424B5 | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 1, 2026 21w ago | 8-K | $18.59 $16.94 | ▼ −8.88% | ▼ −6.13% | $14.50 (−22.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers